ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Allopurinol"

  • Abstract Number: 163 • 2014 ACR/ARHP Annual Meeting

    Is the Rate of Skin Reactions to Febuxostat Increased in Patients with a History of Skin Intolerance to Allopurinol? a Retrospective, Hospital-Based Study Involving 101 Patients Consecutively Treated with Allopurinol and Febuxostat

    Thomas Bardin1, Gérard Chales2, Tristan Pascart3, René-Marc Flipo4, Jean-Claude Roujeau5, Aurélie Delayen6 and Pierre Clerson7, 1Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France, 2Dept of Rheumatology, CHR - Hopital Sud, Rennes, France, 3Rheumatology, Saint-Philibert Hospital, LOMME, France, 4rheumatology, Rene Salengro hospital, Lille, France, 5Dermatology, University Paris Est, Créteil, France, 6Orgamétrie biostatistiques, Roubaix, France, 7Orgametrie, Roubaix, France

    Background/Purpose: Allopurinol can lead to skin toxicity. Minor skin reactions are reported in 2-4% of patients and life threatening severe cutaneous reactions (SCARs) in 0.1-0.4%.…
  • Abstract Number: 46 • 2014 ACR/ARHP Annual Meeting

    Xanthine Oxidase Inhibitors and Risk of Type 2 Diabetes in Patients with Gout

    Seoyoung C. Kim1, John D. Seeger2, Jun Liu3 and Daniel H. Solomon4, 1Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, 3Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, 4Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Hyperuricemia and gout are associated with an increased risk of type 2 diabetes (T2D). Xanthine oxidase inhibitors (XOI), allopurinol and febuxostat, are the main…
  • Abstract Number: L10 • 2014 ACR/ARHP Annual Meeting

    Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Two Phase III Clinical Trials: Combination Study of Lesinurad in Allopurinol Standard of Care Inadequate Responders (CLEAR 1 and 2)

    Kenneth G. Saag1, Scott Adler2, Nihar Bhakta3, Maple Fung3, Jeff Kopicko3, Chris Storgard3 and Thomas Bardin4, 1Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 2AstraZeneca Pharmaceuticals, Wilmington, DE, 3Ardea Biosciences, Inc., San Diego, CA, 4Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France

    Background/Purpose: Inadequate response to allopurinol monotherapy is common. Lesinurad (RDEA594) is a selective uric acid reabsorption inhibitor (SURI) under investigation for treatment of gout in…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies